Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis

J Neuroimmunol. 2014 Mar 15;268(1-2):95-8. doi: 10.1016/j.jneuroim.2014.01.008. Epub 2014 Jan 23.


Fingolimod has demonstrated efficacy in patients with multiple sclerosis (MS), and patients become gradually lymphopenic after a few days of treatment, with selective reductions in CD4+ subsets. We observed an increase in the frequencies of circulating regulatory T cells after fingolimod administration. However, we also found that half of patients had increased proportion of circulating Th17 cells in CD4+ T cells after treatment (including a patient with MS relapses), whereas the others showed lower frequencies of Th17 cells, indicating some variability among patients. Further studies may confirm if slower reduction of circulating Th17 cells following fingolimod initiation predisposes to relapses.

Keywords: Fingolimod; Interleukin-17; Multiple sclerosis; Regulatory T cells; Th17; Treatment.

Publication types

  • Clinical Trial

MeSH terms

  • Cell Separation
  • Female
  • Fingolimod Hydrochloride
  • Flow Cytometry
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / blood*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / immunology
  • Propylene Glycols / therapeutic use*
  • Sphingosine / analogs & derivatives*
  • Sphingosine / therapeutic use
  • T-Lymphocytes, Regulatory / immunology*
  • Th17 Cells / immunology*


  • Immunosuppressive Agents
  • Propylene Glycols
  • Fingolimod Hydrochloride
  • Sphingosine